PegBio Co., Ltd. (02565.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 5.61

From 52W high−92.24%

Volume7.54M

Market capHKD 2.24B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

HKD 5.61

From 52W high

−92.24%

Volume

7.54M

Market cap

HKD 2.24B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

49.1

MomentumView details →

1D Return

+3.76%

YTD Return

−91.60%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+3.76%

YTD Return

−91.60%

1Y Return

−88.34%

RSI (14)

49.1

vs 50D SMA

−3.43%

vs 200D SMA

−83.28%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.08

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 23, 2027 →

Latest newsMore news →

Paige Biopharmaceuticals (02565) signed a material transfer agreement with SN BioScience to apply SN BioScience's SNA long-acting drug delivery platform to three of Paige's metabolic disease peptide candidates including APGP6 for joint research.18d ago

PegBio Co., Ltd. received the first commercialization cooperation payment of about HK$61 million from Tenrui Pharmaceutical under an agreement for the commercialization of Paidakang in mainland China.26d ago

Similar companies

Day One Biopharmaceuticals, Inc.DAWN Aurinia Pharmaceuticals Inc.AUPH BioCryst Pharmaceuticals, Inc.BCRX Ocular Therapeutix, Inc.OCUL Nektar TherapeuticsNKTR Palvella Therapeutics, Inc.PVLA Find similar companies →

Latest newsMore news →

Paige Biopharmaceuticals (02565) signed a material transfer agreement with SN BioScience to apply SN BioScience's SNA long-acting drug delivery platform to three of Paige's metabolic disease peptide candidates including APGP6 for joint research.18d ago PegBio Co., Ltd. received the first commercialization cooperation payment of about HK$61 million from Tenrui Pharmaceutical under an agreement for the commercialization of Paidakang in mainland China.26d ago Rani Therapeutics entered into a research and development collaboration with PegBio to explore oral delivery of novel obesity and metabolic disease molecules using the RaniPill platform.38d ago